Management Partners with Private Equity to Buy Out Antibody Maker

St. Louis, MO 9/17/18; St. Louis, MO 9/19/18—Thompson Street Capital Partners (TSCP) and management have partnered to purchase LifeSpan Biosciences (LSBio). Based in Washington, LSBio develops and distributes antibodies, kits, proteins and additional biological reagents. Financial information was not disclosed. “The Company fills a highly specific niche in its industry and enjoys a well­-deserved reputation for excellence, innovation and customer service,” commented Bob Dunn, a managing director and head of Acquisitions at TSCP. LSBio plans to grow through both internal investments and acquisitions. TSCP has named Dale Gordon as CEO of the company, replacing Bertram Polan, who remains chairman. Mr. Gordon most recently was with GE Healthcare Life Sciences.

Regarding LS Bio’s differentiating factors compared to competitors, a Thompson Street Capital Partners spokesperson told IBO, “LSBio is focused specifically on providing antibodies and related reagents. They have one of the industry’s broadest catalogs with over 500,000 reagents available and researchers have long relied on LSBio’s expertise in immunohistochemistry (IHC) to validate high-quality antibodies.”  The company employs 40 people. Thompson Street’s other biological reagent company holding is BioreclamationIVT.

< | >